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INTRODUCTION
Raised platelet count (thrombocytosis) 
is a newly discovered marker of cancer 
in primary care; the 1-year incidence of 
cancer in patients with thrombocytosis 
has been found to be 11.6% for males 
and 6.2% for females.1 These figures far 
exceed the 3% threshold set by the National 
Institute for Health and Care Excellence 
(NICE) for investigating possible cancer in 
the UK.2 Even marginally raised platelet 
counts are associated with a clinically 
relevant increased risk of cancer,3 although 
the underpinning mechanism(s) for the 
platelet–cancer association are yet to be 
fully characterised. 
Platelet count varies with age and sex,1,3–5 
ethnicity,6,7 and has a genetic component.8 
Despite proposals for tailored reference 
ranges for different ages and sexes,5 current 
UK guidance on interpreting platelet count 
applies a uniform threshold of 400 × 109/l to 
all patients.2,9
Identifying the platelet count at which 
patients are at a ≥3% risk of cancer can 
contribute to the improved selection of 
patients for further investigation in primary 
care and, crucially, avoid unnecessary 
investigation in those with lower risk. 
As such, the authors examined cancer 
incidence, overall and by site, in patients 
with a normal platelet count, stratified by 
age and sex, with particular focus on those 




Electronic primary care medical records for 
this prospective cohort study were extracted 
from the Clinical Practice Research Datalink 
(CPRD) GOLD database. CPRD contains 
anonymised electronic records, including 
all patients’ consultations, diagnoses, and 
laboratory results from approximately 
8% of UK practices. Linkage to data held 
by the National Cancer Registration and 
Analysis Service (NCRAS) was available 
for all patients from English practices; 
this provided a second mechanism for 
identifying cancer diagnoses and the stage 
of cancer at diagnosis.
Patient samples
Eligible patients had a platelet count of 150–
400 × 109/l recorded between 1 May 2005 
and 30 April 2013; were aged ≥40 years at 
the time of the platelet count; and registered 
at a practice with NCRAS cancer registry 
linkage. Two samples were extracted:
• patients who had a platelet count at the 
upper end of the normal range (high-
normal), classified as 326–400 × 109/l. 
Their index date was defined as the date 
of their first high-normal platelet count, 
even if this was not their earliest recorded 
count. This emphasis on sampling 
patients with a high-normal platelet 
count was undertaken to maximise 
power for subgroup analyses. These 
Abstract
Background
A raised platelet count (thrombocytosis) 
measuring >400 × 109/l is associated with 
high cancer incidence. It is uncertain whether 
platelet counts at the upper end of the normal 
range (high-normal: 326–400 × 109/l) are also 
associated with cancer.
Aim
To investigate cancer incidence following a 
normal platelet count in primary care.
Design and setting
A prospective cohort study was undertaken 
using data from the Clinical Practice Research 
Datalink and National Cancer Registration and 
Analysis Service, dating from 1 May 2005 to 30 
April 2014.
Method
One-year cancer incidence was estimated for 
295 312 patients with normal platelet counts 
(150–400 × 109/l). Patients with platelet counts 
>325 × 109/l were oversampled to maximise 
precision of estimates of cancer incidence. All 
patients were aged ≥40 years with no prior 
cancer diagnoses. The effects of age, sex, and 
smoking were explored. Non-melanoma skin 
cancers were omitted from exclusions and 
incidence.
Results
One-year cancer incidence increased greatly with 
age, male sex, and higher platelet count. Males 
aged ≥60 years with a high-normal count had 
an incidence of 4.2% (95% confidence interval 
[CI] = 4.0 to 4.4). The highest incidence of 6.7% 
(95% CI = 5.3 to 8.4) was found in males aged 
≥80 years, who had platelets in the range of 
376–400 × 109/l; this was 3.1 percentage points 
higher than the incidence for patients in the 
same age group with lower-normal counts of 
150–325 × 109/l. Risks for all female subgroups 
were <3%. Patients with high-normal platelet 
counts were most at risk of lung and colorectal 
cancers and, in general, had advanced-stage 
cancer at diagnosis.
Conclusion 
Platelet counts at the high-normal range in 
males aged ≥60 years may be indicative of an 
underlying malignancy, and referral for further 
investigation should be considered. 
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patients were further grouped by platelet 
count: 326–350 × 109/l (high–normal 1); 
351–375 × 109/l (high–normal 2); and 
376–400 × 109/l (high–normal 3); and
• a comparison group of patients with no 
recorded high-normal platelet count 
(lower-normal). Their index date was 
that of their first count in the range of 
150–325 × 109/l. 
Patients were excluded if they had a 
cancer diagnosis prior to the index date 
or a subsequent cancer detected through 
screening. 
Patient characteristics
Sex and age at index date (categorised 
in 10-year bands up to ≥80 years) were 
retrieved from CPRD records. Smoking 
status (‘never’ or ‘past/current’) was 
identified using Read code and product 
code (for smoking cessation therapies) lists 
published by Booth et al.10 Patients’ records 
were examined for alarm symptoms of 
cancer in the 21 days prior to their index 
date.3 
Outcome variables
Incident cancer diagnoses in the year 
following the index date were identified by 
searching patients’ CPRD GOLD records 
for any of the 2182 cancer-related Read 
codes covering 21 specific sites in the body, 
plus a miscellaneous category. This list 
of Read codes (available from the authors 
on request) has been utilised in many 
previous studies. Incident diagnoses for 
the same period were also extracted from 
NCRAS data using 02 (morphology) codes 
from the 10th revision of the International 
Classification of Diseases. As is standard 
practice, non-melanoma skin cancers were 
not studied; as these are largely diagnosed 
visually, identifying blood-based markers is 
not likely to be clinically useful. Diagnoses 
recorded in either the CPRD or NCRAS 
data were accepted, with the earliest record 
in either assigned as the diagnosis date. 
Stage at diagnosis was extracted from 
NCRAS data, where available, and was 
dichotomised as ‘early’ (stages 0–2) or 
‘advanced’ (stages 3–4). 
Sample size
To estimate a cancer incidence of 3% 
(NICE’s recommended threshold for urgent 
referral) with a margin of error of ≤1%, 
a sample size calculation indicated that 
1118 patients were needed per age/sex/
platelet count subgroup. Feasibility counts 
suggested this size would be reached in all 
strata except in males aged ≥80 years in the 
high-normal 3 group. Due to the size of the 
dataset being limited to 300 000 patients as 
a result of budgetary and CPRD restrictions, 
all eligible patients in the high-normal 
groups were included; the remaining 
allocation was given to patients in the 
lower-normal group, for whom an equal-
sized simple random sample (SRS) was 
taken for each of the 10 age/sex subgroups.
Statistical analysis
The 1-year cancer incidence is reported as 
a percentage (with 95% confidence intervals 
[CIs]), stratified by platelet count group, 
age band, and sex, as well as comparative 
baseline cancer incidence (as determined 
from NCRAS-reported national incidence 
figures). For patients in the high-normal 
groups, this is equivalent to the positive 
predictive value (PPV) for cancer of their 
platelet count. Incidence is presented by 
platelet count group for subgroups in which 
a significant increase in incidence was 
observed. 
The most commonly diagnosed cancers 
were identified, together with the proportions 
of patients for whom a high-normal count 
was the first recorded feature of these 
cancers. Odds ratios (ORs) by platelet count 
group for diagnosis with these cancers, and 
any cancer, were obtained from logistic 
regressions that adjusted for age, sex, and 
How this fits in 
The risk of cancer in primary care patients 
with thrombocytosis (an elevated platelet 
count of >400 × 109/l) has been found in 
males and females to be almost four and 
two times above the 3% threshold for 
urgent investigation for suspected cancer 
set by the National Institute for Health and 
Care Excellence, respectively. The authors 
investigated patients with a platelet count 
at the upper end of the normal range 
(high-normal: 326–400 × 109/l) to help 
determine whether cancer should be 
considered. It was found that older males 
with a high-normal platelet count have 
an increased incidence of cancer within 
1 year compared with those with a count 
that is well within the normal range. At the 
upper end of the normal range, colorectal 
cancer was most likely to be diagnosed 
in males and so, in the absence of any 
other indicative clinical features, a faecal 
immunochemical test may be the most 
appropriate initial investigation. These 
findings support the usefulness of platelet 
count as a clue to identifying patients who 
could be harbouring a cancer. 
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smoking history; these utilised the full 
sample. 
A further logistic regression model was 
constructed to investigate the association 
between a high-normal count and advanced 
stage at diagnosis, which controlled for 
patients’ age, sex, smoking history, and site 
of diagnosed cancer. This model included 
all patients with diagnosed cancer and 
complete staging information.
Analyses were conducted using Stata/
SE (version 15.0), and results reported in 
accordance with the Strengthening the 
Reporting of Observational Studies in 
Epidemiology (STROBE) statement.11
RESULTS
The final sample consisted of 226 262 
patients with high-normal counts, and 
69 050 patients with a lower-normal count 
(Figure 1). The median age for patients 
in the high-normal groups was 60 years 
(interquartile range 47–71 years) and 
158 081 (69.9%) were female. An SRS of 
6995 patients in the lower-normal group 
was taken for each age/sex subgroup; 
demographics are not reported as the 
methods created an artificial population.
Cancer diagnoses
A total of 5178 incident cancers were 
recorded in the data sources. In total, 762 
were only recorded in the CPRD, 866 were 
only recorded by NCRAS, and 3550 incident 
cancers were reported in both. In 68 181 
male patients from the high-normal groups, 
there were 1869 incident cancers diagnosed 
within 1 year (2.7%; 95% CI = 2.6 to 2.9). 
In contrast, of 158 081 female patients in 
the high-normal groups, there were 2206 
cancers (1.4%; 95% CI = 1.3 to 1.5). The 
comparable incidences for patients in the 
low-normal group were 2.1% (95% CI = 2.0 
to 2.3) for males and 1.1% (95% CI = 1.0 
to 1.1) for females. Regression models 
showed increases in the risk of cancer with 
increasing platelet count, adjusted for sex, 
age, and smoking status (Table 1). 
Figure 2 displays 1-year incidence of 
cancer by age band for patients in the high-
normal and lower-normal groups, together 
with NCRAS-recorded incidence rates 
for England in 2016 (when NCRAS was 
formed in a merger of the National Cancer 
Intelligence Network and National Disease 
Registration), stratified by sex. Incidence 
increased with age for both males and 
females, although no female subgroup’s 
incidence surpassed the 3% NICE risk 
threshold; for that reason, females were 
excluded from subsequent descriptive 
analyses. For males, however, significantly 
higher incidences were evident for patients 
with a high-normal count relative to low-
normal counts for all but the youngest age 
group.
Table 2 displays the 1-year cancer 
incidences for males stratified by age 
band and platelet count (corresponding 
incidences for females can be found in 
Supplementary Table S1). All high-normal 
subgroups for males aged ≥60 years 
met the NICE threshold for referral; 
among these, the lowest incidence was 
in 60–69-year-olds in the high-normal 1 
group at 3.0% (95% CI = 2.7 to 3.4) and 
was highest in ≥80-year-olds in the high-
normal 3 group at 6.7% (95% CI = 5.3 to 
8.4); this represents an absolute increase 
in cancer risk of 3.1 percentage points over 
males with lower-normal platelet counts in 
the same age group. Overall, the incidence 
for a high-normal count for males aged 
≥60 years was 4.2% (95% CI = 4.0 to 4.4).
Site of diagnosed cancers
For males aged ≥60 years in the high-
normal groups the most common incident 
cancers within 1 year were prostate, 
colorectal, and lung (Figure 3). Two less-
common cancers, oesophagogastric and 
bladder, are also shown; these appear 
to only have an association with platelet 
counts of >400 × 109/l. Including all 295 312 
High-normal (326–400 × 109/l) Lower-normal (150–325 × 109/l)
260 140 patients aged
≥40 years
732 014 patients aged
≥40 years
Pre-existing cancer
(CPRD), n = 69 023
Simple random sample
selected for each of 10
age/sex strata, n = 6995
Pre-existing cancer
(NCRAS cancer registry), 
n = 603
Cancer detected via
screening, n = 297
Pre-existing cancer
(CPRD), n = 30 097
Pre-existing cancer
(NCRAS cancer registry), 
n = 2423
Cancer detected via
screening, n = 1358
Included, N = 226 262
Included, N = 69 050
N = 662 991
N = 69 950
Figure 1. Cohort identification flowchart.  
CPRD = Clinical Practice Research Datalink. 
NCRAS = National Cancer Registration and Analysis 
Service.
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patients, logistic regressions (Table 1) 
showed that a platelet count of 376–
400 × 109/l was associated with odds nearly 
five times greater than that for patients in 
the lower-normal group for lung cancer 
(OR 4.68; 95% CI = 2.79 to 7.87), and nearly 
four times greater for colorectal cancer 
(OR 3.93; 95% CI = 3.12 to 4.97). 
Sensitivity analyses for the all-cancer 
model confirmed that:
• the magnitude of effect of having a 
high-normal platelet count did not differ 
between males and females (interaction 
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count (150–325 × 109/l)
High-normal platelet 
count (326–400 × 109/l)
Figure 2. One-year incidence of all cancers (excluding 
non-melanoma skin cancers) across age and platelet 
groups.  NCRAS = National Cancer Registration and 
Analysis Service. NICE = National Institute for Health 
and Care Excellence.
Table 1. Regression models predicting 1-year incidence of all cancers, lung cancer, and colorectal cancera
Covariate All cancers, ORb (95% CI) P-value Lung cancer, ORb (95% CI) P-value Colorectal cancer, ORb (95% CI) P-value
Age, years       
 40–49 (reference) 1.00 — 1.00 — 1.00 — 
 50–59 1.72 (1.54 to 1.93) <0.001 3.94 (1.97 to 7.89) <0.001 2.61 (1.88 to 3.61) <0.001 
 60–69 2.88 (2.60 to 3.20) <0.001 9.11 (4.74 to 17.49) <0.001 5.36 (3.96 to 7.26) <0.001 
 70–79 4.30 (3.88 to 4.76) <0.001 10.5 (5.44 to 20.26) <0.001 9.74 (7.26 to 13.08) <0.001 
 ≥80 4.30 (3.86 to 4.79) <0.001 7.55 (3.74 to 15.23) <0.001 9.44 (6.94 to 12.84) <0.001
Sex       
 Female (reference) 1.00 — 1.00 — 1.00 — 
 Male 2.01 (1.90 to 2.13) <0.001 1.63 (1.26 to 2.09) <0.001 2.01 (1.77 to 2.29) <0.001
Smoking status       
 Non-smoker (reference) 1.00 — 1.00 — 1.00 — 
 Past/current smoker 1.01 (0.94 to 1.07) 0.868 3.71 (2.41 to 5.70) <0.001 0.88 (0.77 to 1.01) 0.079
Platelet count (× 109/l)       
 150–325 (reference) 1.00 — 1.00 — 1.00 — 
 326–350 1.36 (1.26 to 1.47) <0.001 3.84 (2.38 to 6.19) <0.001 2.60 (2.10 to 3.22) <0.001 
 351–375 1.56 (1.44 to 1.70) <0.001 4.49 (2.73 to 7.37) <0.001 3.76 (3.02 to 4.68) <0.001 
 376–400 1.63 (1.49 to 1.79) <0.001 4.68 (2.79 to 7.87) <0.001 3.93 (3.12 to 4.97) <0.001
aEach model used data from all 295 312 patients. bORs of >1 indicate increased odds of cancer relative to the reference group; ORs of <1 indicate decreased odds. CI = confidence 
interval. OR = odds ratio.
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• effects did not substantially alter when 
outcomes were restricted to NCRAS-
recorded cancers only. 
Other features of cancer
Of males in the high-normal groups aged 
≥60 years, 65 (74.7%) of the 87 diagnosed 
with lung cancer, and 164 (68.9%) of the 
238 diagnosed with colorectal cancer, had 
no recorded alarm features of cancer in the 
21 days before their index platelet count.
Stage at diagnosis
Of 4416 NCRAS-recorded incident cancers, 
1855 (42.0%) had staging information: 
720 (38.8%) of those indicated that the 
cancer was advanced. Missingness was 
random with respect to platelet count. 
After controlling for age, sex, and smoking 
status, a high-normal count represented 
an increase of nearly 50% in the odds 
of advanced stage at diagnosis (OR 1.5; 
95% CI = 1.22 to 1.97) (data not shown).
DISCUSSION
Summary
This study of nearly 300 000 patients with 
a normal platelet count (150–400 × 109/l) 
in primary care found the 1-year incidence 
of any type of cancer increased in male 
patients aged ≥60 years who presented 
with a platelet count of ≥326 × 109/l. For 
female patients, the risk of cancer did 
not meet the UK’s agreed threshold for 
urgent investigation in any age/platelet-
count group, although cancer became more 
common in both sexes with higher platelet 
counts. Patients with high-normal counts 
were at 50% increased risk of advanced-
stage cancer at diagnosis.
The odds of being diagnosed with cancer 
were up to 4.7 times higher for lung cancer 
and 3.9 times higher for colorectal cancer 
for those patients who had high-normal 
counts relative to the comparison group. 
Strengths and limitations 
Key strengths of this study are the size of 
the cohort, its primary care setting, and its 
prospective design, allowing for precise and 
reliable estimates of cancer incidence in the 
clinical setting where suspicion of cancer 
most commonly arises. The platelet results 
were transferred electronically to patient 
records in the CPRD, minimising missing 
data and possible recording errors. The 
NCRAS linkage is also a strength: 82.3% of 
CPRD-recorded cancers were also recorded 
in NCRAS. Only 768 of the total 5178 (14.8%) 
cancers were recorded solely in the CPRD, a 
figure similar to that found in other studies.1
Table 2. One-year cancer incidence (95% CI) for males by age band and platelet group, with comparable 
national incidence
 Platelet group
 National Lower-normal: High-normal 1: High-normal 2: High-normal 3:  
Age band, years incidence 150–325 × 109/l 326–350 × 109/l 351–375 × 109/l 376–400 x 109/l
40–49  n = 6984a n = 8230 n = 4492 n = 2617 
 0.2 (0.1 to 0.2) 0.5 (0.3 to 0.7) 0.7 (0.5 to 0.9) 0.7 (0.5 to 1.0) 0.5 (0.3 to 0.9) 
50–59  n = 6976 n = 9523 n = 5223 n = 3070 
 0.5 (0.5 to 0.6) 1.1 (0.9 to 1.4) 1.7 (1.4 to 2.0) 1.6 (1.4 to 2.0) 1.9 (1.4 to 2.4) 
60–69  n = 6953 n = 9286 n = 5122 n = 3138 
 1.5 (1.4 to 1.5) 2.0 (1.7 to 2.3) 3.0 (2.7 to 3.4) 3.2 (2.8 to 3.7) 3.8 (3.1 to 4.5) 
70–79  n = 6915 n = 6206 n = 3620 n = 2186 
 2.6 (2.5 to 2.7) 3.5 (3.1 to 4.0) 4.7 (4.2 to 5.3) 5.8 (5.1 to 6.6) 5.3 (4.4 to 6.3) 
≥80  n = 6851 n = 2826 n = 1582 n = 1060 
 3.5 (3.4 to 3.6) 3.6 (3.2 to 4.1) 4.7 (4.0 to 5.6) 5.1 (4.0 to 6.3) 6.7 (5.3 to 8.4)




































incidence in England 2016
Lower-normal platelet
count (150–325 × 109/l)
High-normal platelet
count (326–400 × 109/l)
High platelet
count (>400 × 109/l)
Figure 3. One-year incidence for the most common 
cancer sites in males aged ≥60 years. Vertical solid 
black lines indicate 95% confidence intervals. Data for 
‘High platelet count (>400 × 109/l)’ group taken from 
the dataset described in Bailey et al.1 NCRAS = National 
Cancer Registration and Analysis Service. 
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Blood tests in UK primary care are 
generally ordered when a clinician wants 
to explore possible reasons for a patient’s 
reported ill health. This selects a population 
somewhat more ‘ill’ than the untested 
population. The increased cancer incidence 
in the sample presented here relative to 
the expected value (from national incidence 
figures) will, in part, reflect this. However, 
the study design included a comparison 
sample with the same blood test taken, 
allowing the authors to identify absolute 
risk increases; this may explain the different 
histograms in Figure 3. 
Prostate cancer incidence was higher in 
those who were tested than in the NCRAS 
recorded data for the general population, 
essentially irrespective of the platelet 
result. This suggests little or no true 
association between high platelet counts 
(or thrombocytosis) and prostate cancer. In 
contrast, a lower-normal platelet count has 
the same colorectal cancer incidence as 
the general population, but the incidence 
is higher with high-normal counts, and 
much higher with thrombocytosis. Even 
more notable is the lung cancer–platelet 
relationship, in which low-normal platelet 
counts provide some genuine reassurance; 
the cancer risk is lower than baseline 
with such a result. However, high-normal 
and thrombocytosis results suggest a 
considerably increased lung cancer risk. 
One limitation is that the PPVs reported 
here are for high-normal counts following 
primary care testing, but the indication for 
the blood test was unknown — GPs rarely 
record reasons for blood tests. A second 
limitation is that it was not possible to study 
ethnicity as this was poorly recorded in the 
CPRD. 
Comparison with existing literature
To the authors' knowledge, this is the first 
study to report cancer incidence stratified 
by age and sex for patients with high-
normal platelet counts. Cancer incidences 
for patients with platelet counts within 
the normal range were lower than those 
reported for patients with thrombocytosis.1 
Age,4 ethnicity,6,7 and other genetic factors8 
influence the platelet count; a number 
of studies have called for updated age-, 
sex-, and ethnicity-based platelet reference 
ranges,4–6,12 but no primary care-based 
studies have taken these factors into 
account when examining platelet counts 
and cancer diagnosis to date. The study 
presented here supports the argument that 
it would be clinically useful to adopt different 
reference ranges for platelet count, based 
on age and sex. 
In the present study, lung and colorectal 
cancers were particularly associated 
with high-normal platelet counts. The 
lungs are a site of especial importance in 
platelet production, perhaps contributing 
to the findings.13–15 Colorectal cancer is 
frequently accompanied by bleeding into the 
gastrointestinal tract, perhaps provoking 
increased platelet production, although the 
authors were unable to study this. 
Implications for research and practice
This study found that females with a high-
normal platelet count are at low risk of 
possible cancer, and the incidence of cancer 
in these groups falls below the thresholds 
stipulated by NICE guidance2 that warrant 
further investigation. However, that does 
not mean that platelet count cannot be 
diagnostically useful in females. Females 
have higher platelet counts than males, 
primarily due to the effects of oestrogen 
on platelet-forming processes in the bone 
marrow;16 the higher baseline platelet 
count in females means that any increase 
in accompanying malignancy will likely 
occur over the currently accepted ‘normal’ 
threshold of 400 × 109/l. 
There is no evidence for differential 
cancer–platelet effects in the two sexes. 
Observed changes in platelet count, rather 
than the absolute count, may be a more 
clinically useful measure for the early 
detection of cancer. This has not been fully 
explored in observational research studies 
and should be a focus for future research. 
The PPVs inform clinicians of the cancer-
related implications of a high-normal 
platelet count result, irrespective of the 
reason for testing. However, they should 
not be interpreted as evidence to support 
measuring a platelet count specifically to 
identify, or refute, cancer. In effect, the high-
normal results in males should be seen as 
a marker of possible cancer in a similar way 
to a symptom of possible cancer.
Given the current accepted upper range 
of ‘normal’ platelet count of 400 × 109/l for 
adults in the UK, and in the absence of any 
national initiative to change that, the key 
clinical implication from this study is that a 
platelet count of >325 × 109/l in males, and 
any unexplained increase to >400 × 109/l 
in females, should prompt clinicians to 
consider possible cancer. The higher risk 
ratios associated with lung and colorectal 
cancer mean that faecal immunochemical 
testing and chest X-ray are reasonable first 
investigations in the absence of any other 
symptoms that may suggest a specific 
cancer or alternative diagnosis.
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